keyword
https://read.qxmd.com/read/20528335/valuing-healthcare-under-taiwan-s-national-health-insurance
#21
JOURNAL ARTICLE
Wen-Yi Chen, Jwo-Leun Lee, Yia-Wun Liang, Chin-Tun Hung, Yu-Hui Lin
This paper provides a new assessment of the most recent premium policy - the second-generation National Health Insurance (NHI) policy under Taiwan's NHI system. The willingness to pay (WTP) value for a universal coverage NHI plan is NT$201 per month and NT$940 per month for an individual level and for a household level, respectively. We find that the WTP rate is approximately 3.89% of monthly household income, consistent with the range of the new premium rate (2.5-4% of monthly household income) proposed by Taiwan's government...
October 2008: Expert Review of Pharmacoeconomics & Outcomes Research
https://read.qxmd.com/read/20456248/efficacy-and-safety-of-nt-201-for-upper-limb-spasticity-of-various-etiologies-a-randomized-parallel-group-study
#22
RANDOMIZED CONTROLLED TRIAL
M Barnes, A Schnitzler, L Medeiros, M Aguilar, A Lehnert-Batar, P Minnasch
OBJECTIVE: To assess efficacy and safety of two dilutions of botulinum neurotoxin type A NT 201 (Xeomin®) in patients with upper limb spasticity of diverse etiology. METHODS: Changes in functional disability and muscle tone from baseline to week 4 after NT 201 treatment. RESULTS: One hundred ninety-two patients with stroke, brain injury, multiple sclerosis, or cerebral palsy were randomized to either 50 or 20 U/ml NT 201 dilutions. The maximum total NT 201 dose was 495 units...
October 2010: Acta Neurologica Scandinavica
https://read.qxmd.com/read/20230781/mapping-of-the-minimal-internal-ribosome-entry-site-element-in-the-human-embryonic-stem-cell-gene-oct4b-mrna
#23
JOURNAL ARTICLE
Wei Zhang, Xia Wang, Zhifeng Xiao, Weiquan Liu, Bing Chen, Jianwu Dai
The OCT4 gene is an important regulator of self-renewal in embryonic stem cells and can generate three spliced variants, OCT4A, OCT4B, and OCT4B1. In OCT4B, the single mRNA can generate at least three protein isoforms, OCT4B-164, OCT4B-190, and OCT4B-265, using alternative translation initiation. OCT4B-164 and OCT4B-190 can be translated by an internal ribosome entry site (IRES)-mediated mechanism. Our work previously demonstrated that nucleotides (nt) 102-326 contained an IRES. We have mapped a 30-nt sequence (nt 201-231), which is sufficient to promote internal initiation of translation of OCT4B mRNA...
April 9, 2010: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/19644361/efficacy-and-safety-of-botulinum-neurotoxin-nt-201-in-poststroke-upper-limb-spasticity
#24
RANDOMIZED CONTROLLED TRIAL
Petr Kanovský, Jaroslaw Slawek, Zoltan Denes, Thomas Platz, Irena Sassin, Georg Comes, Susanne Grafe
OBJECTIVE: To assess the impact of the new botulinum neurotoxin type A preparation NT 201 (Xeomin; Merz Pharmaceuticals GmbH, Frankfurt, Germany) on muscle tone, functional disability, and caregiver burden in patients with poststroke upper limb spasticity in a randomized, placebo-controlled, double-blind study. METHODS: One hundred forty-eight patients with an Ashworth Scale score of 2 or higher for wrist and finger flexors and at least moderate disability in their principal therapeutic target of the Disability Assessment Scale were treated either with NT 201 (median, 320 U) or placebo and followed up for up to 20 weeks...
September 2009: Clinical Neuropharmacology
https://read.qxmd.com/read/17982511/gateways-to-clinical-trials
#25
JOURNAL ARTICLE
M Bayes, X Rabasseda, J R Prous
12B75, 274150; Abacavir sulfate/lamivudine, Abatacept, Ad2/HIF-1alpha, Adalimumab, Adefovir, Adefovir dipivoxil, AGN-201904-Z, AIDSVAX, Albinterferon alfa-2b, Alemtuzumab, Aliskiren fumarate, Alvimopan hydrate, Amlodipine besylate/atorvastatin calcium, Amlodipine besylate/Olmesartan medoxomil, Ammonium tetrathiomolybdate, Amodiaquine, Apaziquone, Aprepitant, Arsenic trioxide, Artesunate/Amodiaquine, Ascorbic acid, Atazanavir sulfate, Atazanavir/ritonavir, Atomoxetine hydrochloride, Atrigel-Leuprolide, Axitinib; Bevacizumab, Binodenoson, Bortezomib, Bovine lactoferrin; Calcipotriol/betamethasone dipropionate, Carisbamate, Certolizumab pegol, Ciclesonide, Conivaptan hydrochloride, CP-690550, CP-751871, Cypher; Dapivirine, Darbepoetin alfa, Darunavir, Dasatinib, del-1 Genemedicine, Denosumab, Desloratadine, Dexlansoprazole, DiabeCell, Drospirenone/ethinylestradiol, DTaP-HepB-IPV, Duloxetine hydrochloride, Dutasteride; Eculizumab, Eldecalcitol, Eletriptan, Emtricitabine, Entecavir, Eritoran tetrasodium, Ertapenem sodium, Escitalopram oxalate, Eslicarbazepine acetate, Esomeprazole magnesium, Estradiol acetate, Eszopiclone, ETEC vaccine, Etoricoxib, Exenatide, Ezetimibe; Fluticasone furoate, Fosmidomycin, Fosmidomycin/clindamycin; Glutamine; Heat Shock Protein 10, Hepatitis B hyperimmunoglobulin, HIV vaccine, Hochuekki-to, Human Albumin, Human papillomavirus vaccine; Immune globulin subcutaneous [human], IMP-321, Interferon omega, ISIS-301012, Istaroxime; Japanese encephalitis virus vaccine; Latanoprost/timolol maleate, Lenalidomide, Linaclotide acetate, Lumiracoxib, LY-517717; Malaria vaccine, MAS-063D, Meningitis B vaccine, Mepolizumab, Methylnaltrexone bromide, Micafungin sodium, MK-0822A, Morphine glucuronide, Morphine hydrochloride, Mycophenolic acid sodium salt; Natalizumab, Nesiritide, Norelgestromin/ethinyl estradiol, NT-201; Oblimersen sodium, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Omalizumab, Otamixaban; Paclitaxel nanoparticles, Panitumumab, Panobinostat, Parathyroid hormone (human recombinant), Parecoxib sodium, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pegvisomant, PI-88, Pimecrolimus, Pneumococcal 7-valent conjugate vaccine, Pneumococcal 9-valent conjugate vaccine, Pneumococcal conjugate vaccine, Poloxamer-188, Prasugrel, Pregabalin, Prulifloxacin; R-109339, Ramipril/amlodipine, Ranolazine, Rasburicase, rHA influenza vaccine, Ro-50-3821, Rosuvastatin calcium, Rotavirus vaccine, Rotigotine, Ruboxistaurin mesilate hydrate; Satavaptan, SC-75416, Solifenacin succinate, Sorafenib, Sugammadex sodium, Sunitinib malate, Synthetic conjugated estrogens B; Tadalafil, Talnetant, Taxus, Tegaserod maleate, Telbivudine, Temsirolimus, Tenofovir disoproxil fumarate, Tetomilast, Tiotropium bromide, Tipifarnib, Tofimilast, Tremelimumab, Trimethoprim; Udenafil, Urocortin 2; Valdecoxib, Vernakalant hydrochloride; XP-828L...
September 2007: Methods and Findings in Experimental and Clinical Pharmacology
https://read.qxmd.com/read/17414940/neurophysiological-double-blind-trial-of-a-botulinum-neurotoxin-type-a-free-of-complexing-proteins
#26
RANDOMIZED CONTROLLED TRIAL
Kai Wohlfarth, Christian Müller, Irena Sassin, Georg Comes, Susanne Grafe
OBJECTIVE: Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS: Electroneurographic assessments with surface electrodes were performed after single injections of NT 201 (2, 4, 16, or 32 units) into the extensor digitorum brevis (EDB) muscle and the same dose (Botox; Allergan Pharmaceuticals (Ireland) Ltd...
2007: Clinical Neuropharmacology
https://read.qxmd.com/read/17385940/botulinum-neurotoxin-type-a-free-of-complexing-proteins-xeomin-in-focal-dystonia
#27
REVIEW
Wolfgang H Jost, Jörg Blümel, Susanne Grafe
Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It is also known to relieve hemifacial spasm and focal spasticity in children and adults. In addition, BTX-A has been shown to be effective in a wide range of other indications, such as gastrointestinal disorders, hyperhidrosis and cosmetic wrinkle correction (e.g. glabellar frown lines). A new formulation of BTX-A, NT 201 (XEOMIN((R))) has been developed...
2007: Drugs
https://read.qxmd.com/read/15959841/efficacy-and-safety-of-a-new-botulinum-toxin-type-a-free-of-complexing-proteins-in-the-treatment-of-blepharospasm
#28
RANDOMIZED CONTROLLED TRIAL
P Roggenkämper, W H Jost, K Bihari, G Comes, S Grafe
NT 201 is a new development of Botulinum Toxin Type A free of complexing proteins. In this double-blind Phase III trial, we compared the efficacy and safety of NT 201 and BOTOX in patients suffering from blepharospasm. Of 304 enrolled patients, 300 patients received study medication (intent-to-treat population), and 256 patients completed the study as planned (per-protocol population). At baseline, patients received a single injection of NT 201 or BOTOX (<or=35 units per eye). No significant differences were found between NT 201 and BOTOX for all efficacy and safety variables three weeks after injection...
March 2006: Journal of Neural Transmission
https://read.qxmd.com/read/15955951/a-new-botulinum-toxin-type-a-free-of-complexing-proteins-for-treatment-of-cervical-dystonia
#29
RANDOMIZED CONTROLLED TRIAL
R Benecke, W H Jost, P Kanovsky, E Ruzicka, G Comes, S Grafe
A new botulinum toxin type A free of complexing proteins (NT 201) was compared with BOTOX in patients with cervical dystonia by means of a double-blind noninferiority trial. Four hundred sixty-three patients received IM injections of 70 to 300 U of NT 201 or BOTOX and were followed up over 16 weeks. The study clearly shows that NT 201 is at least as effective and safe as BOTOX.
June 14, 2005: Neurology
https://read.qxmd.com/read/15526142/efficacy-and-tolerability-of-a-botulinum-toxin-type-a-free-of-complexing-proteins-nt-201-compared-with-commercially-available-botulinum-toxin-type-a-botox-in-healthy-volunteers
#30
RANDOMIZED CONTROLLED TRIAL
W H Jost, A Kohl, S Brinkmann, G Comes
PURPOSE: This randomized controlled trial was performed to compare the novel botulinum toxin type A free of complexing proteins (NT 201) with the marketed preparation BOTOX degrees regarding efficacy and tolerability. METHODS: Fourteen healthy volunteers received a single intramuscular injection into the extensor digitorum brevis (EDB) muscle of either 4 units NT 201, or 4 units of BOTOX degrees randomised by foot. Compound muscle action potential (CMAP) measurements were recorded for up to 90 days after injection...
July 2005: Journal of Neural Transmission
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.